{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:05:41Z","timestamp":1783656341493,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016827","name":"Deciphera Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03307-3","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T08:22:18Z","timestamp":1752999738000},"page":"4540-4555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics and Safety of Ripretinib in Participants with Hepatic Impairment: A Phase\u00a01 Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Anna","family":"Papinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Abane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Psoinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"issue":"7","key":"3307_CR1","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase\u00a03 trial. Lancet Oncol. 2020;21(7):923\u201334.","journal-title":"Lancet Oncol"},{"key":"3307_CR2","unstructured":"Deciphera Pharmaceuticals LLC. QINLOCK\u00ae (ripretinib) tablets, for oral use. Prescribing information. 2025. https:\/\/www.qinlockhcp.com\/content\/files\/qinlock-prescribing-information.pdf. Accessed 2025 May\u00a015."},{"issue":"5","key":"3307_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","volume":"35","author":"BD Smith","year":"2019","unstructured":"Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738\u201351 e9.","journal-title":"Cancer Cell"},{"issue":"27","key":"3307_CR4","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1080\/14796694.2024.2376521","volume":"20","author":"S George","year":"2024","unstructured":"George S, Blay JY, Chi P, et al. The INSIGHT study: a randomized, phase\u00a0III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17\/18 mutations. Future Oncol. 2024;20(27):1973\u201382.","journal-title":"Future Oncol"},{"issue":"2","key":"3307_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-023-02734-5","volume":"30","author":"MC Heinrich","year":"2024","unstructured":"Heinrich MC, Jones RL, George S, et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase\u00a03 INTRIGUE trial. Nat Med. 2024;30(2):498\u2013506.","journal-title":"Nat Med"},{"issue":"10","key":"3307_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cpdd.1110","volume":"11","author":"X Li","year":"2022","unstructured":"Li X, Shelton MJ, Wang J, Meade J, Ruiz-Soto R. Effects of CYP3A inhibition, CYP3A induction, and gastric acid reduction on the pharmacokinetics of ripretinib, a switch control KIT tyrosine kinase inhibitor. Clin Pharmacol Drug Dev. 2022;11(10):1165\u201376.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"373","key":"3307_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110400","volume":"1","author":"C Pan","year":"2023","unstructured":"Pan C, Cheng Y, He Q, et al. Evaluating the impact of co-administered drug and disease on ripretinib exposure: a physiologically-based pharmacokinetic modeling approach. Chem Biol Interact. 2023;1(373):110400.","journal-title":"Chem Biol Interact"},{"issue":"28","key":"3307_CR8","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1200\/JCO.20.00522","volume":"38","author":"F Janku","year":"2020","unstructured":"Janku F, Abdul Razak AR, Chi P, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase\u00a0I study of ripretinib. J Clin Oncol. 2020;38(28):3294\u2013303.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3307_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3748\/wjg.v22.i3.1260","volume":"22","author":"P Palatini","year":"2016","unstructured":"Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol. 2016;22(3):1260\u201378.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3307_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jceh.2014.08.007","volume":"4","author":"M Bernardi","year":"2014","unstructured":"Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol. 2014;4(4):302\u201311.","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"3307_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bcp.15990","volume":"90","author":"S Armani","year":"2024","unstructured":"Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug-drug interactions. Br J Clin Pharmacol. 2024;90(4):942\u201358.","journal-title":"Br J Clin Pharmacol"},{"key":"3307_CR12","unstructured":"HealthCare Pharmaceuticals Inc. STIGVARA (regorafenib) tablets, for oral use. Prescribing information. 2025. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Stivarga_PI.pdf. Accessed 10 Apr 2025."},{"key":"3307_CR13","unstructured":"Novartis Pharmaceuticals Corporation. GLEEVEC (imatinib mesylate) tablets, for oral use. Prescribing Information. 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/gleevec_tabs.pdf. Accessed 10 Apr 2025."},{"key":"3307_CR14","unstructured":"Pfizer labs. SUTENT (sunitinib malate) capsules, for oral use. Prescribing information. 2021. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=607. Accessed 2025 Apr 10."},{"issue":"12","key":"3307_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361.","journal-title":"Eur J Clin Pharmacol"},{"key":"3307_CR16","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Guidance for industry pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. https:\/\/www.fda.gov\/media\/71311\/download. Accessed 2024 May\u00a021."},{"key":"3307_CR17","unstructured":"European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf. Accessed 2025 Apr 14."},{"issue":"11","key":"3307_CR18","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Ripretinib: first approval. Drugs. 2020;80(11):1133\u20138.","journal-title":"Drugs"},{"issue":"2","key":"3307_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/cc11218","volume":"16","author":"M Bernardi","year":"2012","unstructured":"Bernardi M, Maggioli C, Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care. 2012;16(2):211.","journal-title":"Crit Care"},{"issue":"31","key":"3307_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026835","volume":"100","author":"K Kawaguchi","year":"2021","unstructured":"Kawaguchi K, Sakai Y, Terashima T, et al. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. Med (Baltim). 2021;100(31):e26835.","journal-title":"Med (Baltim)"},{"key":"3307_CR21","unstructured":"Food and Drug Administration. Center for drug evaluation and research. Ripretinib clinical pharmacology and biopharmaceutics review. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213973Orig1s000MultidisciplineR.pdf. 2024 May\u00a030."},{"key":"3307_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2021.07.010","volume":"155","author":"S George","year":"2021","unstructured":"George S, Chi P, Heinrich MC, et al. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021;155:236\u201344.","journal-title":"Eur J Cancer"},{"key":"3307_CR23","unstructured":"Deciphera Pharmaceuticals LLC. QINLOCK (ripreitnib) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/qinlock-epar-product-information_en.pdf. Accessed 2025 Apr 17."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03307-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03307-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03307-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:52:24Z","timestamp":1757260344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03307-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3307"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03307-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Papinska reports employment with Deciphera Pharmaceuticals, LLC (self). Lakshmi Viswanathan reports employment with Deciphera Pharmaceuticals, LLC (self). Qiang Lu reports employment with Deciphera Pharmaceuticals, LLC (self). Farida Abane reports employment with Deciphera Pharmaceuticals, LLC (self). Charles Psoinos reports employment with Deciphera Pharmaceuticals, LLC (self). Rodrigo Ruiz-Soto was employed by and reported royalties from\u00a0Deciphera Pharmaceuticals, LLC at the time the research was conducted (self). As of October 2024, Rodrigo Ruiz-Soto is affiliated with AntibodyChem Biosciences (Newton, MA, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All methods and procedures were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice. The protocol was approved by the IRB IntegReview and by the FDA. According to FDAAA Sect.\u00a0801, Final Rule (42 CFR Part 11), phase\u00a01 trials are not considered applicable clinical trials requiring registration in a public registry. As a phase\u00a01 clinical trial conducted only in the USA, this trial was not registered on ClinicalTrials.gov. All individuals provided written informed consent prior to enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}